PHILM Stock Overview

A biotechnology company, develops drugs for oncology and chronic inflammatory diseases. More details

PHILM fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	1/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Rewards

Revenue is forecast to grow 4.85% per year

Risk Analysis

Shares are highly illiquid

Earnings have declined by 30.1% per year over past 5 years

My Notes

Capture your thoughts, links and company narrative

Philogen S.p.A. Competitors

Avacta Group

AIM:AVCT

UK£193.9m

Oxford Biomedica

LSE:OXB

UK£430.6m

Bioventix

AIM:BVXP

UK£167.0m

Genus

LSE:GNS

UK£1.2b

Price History & Performance

Summary of share price highs, lows and changes for Philogen
Historical stock prices
Current Share Price	€15.20
52 Week High	€15.20
52 Week Low	€15.20
Beta	0.15
1 Month Change	0%
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	4.97%

Recent updates

Shareholder Returns

	PHILM	GB Biotechs	GB Market
7D	0%	9.3%	3.2%
1Y	n/a	-18.6%	10.9%

Return vs Industry: Insufficient data to determine how PHILM performed against the UK Biotechs industry.

Return vs Market: Insufficient data to determine how PHILM performed against the UK Market.

Price Volatility

Is PHILM's price volatile compared to industry and market?
PHILM volatility
PHILM Average Weekly Movement	n/a
Biotechs Industry Average Movement	8.5%
Market Average Movement	4.8%
10% most volatile stocks in GB Market	10.7%
10% least volatile stocks in GB Market	2.6%

Stable Share Price: PHILM has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine PHILM's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1996	157	Dario Neri	www.philogen.com

Philogen S.p.A., a biotechnology company, develops drugs for oncology and chronic inflammatory diseases. It is developing Nidlegy, a combination of the immunocytokines L19IL2 and L19TNF developed intralesional treatment for locoregional melanoma and non-melanoma skin cancers; Fibromun, a human immunomodulatory product consisting of L19 antibody and TNF to treat soft tissue sarcoma, leiomyosarcoma, and glioma; and Darleukin (L19IL2), a human immunostimulatory product consisting of the human L19 antibody fused to the human cytokine interleukin-2 (IL2), which is in phase II clinical trial for the treatment of non-small cell lung cancer. The company is also developing Dodekin, a human immunostimulatory product that comprises vascular targeting antibody fused to interleukin-12 that is in phase I/II clinical trial to treat advanced solid tumors; Dekavil (F8IL10), an anti-inflammatory product, which is in phase I clinical trial for the treatment of chronic inflammation; Onco IX (PHC-102), a 99mTc labelled small molecule radiotracer for the non-invasive detection of carbonic anhydrase IX (CAIX) expressing solid tumors that is in phase 1 clinical trial; and OncoFAP, a small molecule radiotracer for the non-invasive detection of various metastatic solid tumors targeting fibroblast activation protein, which is in phase 1 clinical trial.

Philogen S.p.A. Fundamentals Summary

How do Philogen's earnings and revenue compare to its market cap?
PHILM fundamental statistics
Market cap	€452.97m
Earnings (TTM)	-€5.38m
Revenue (TTM)	€26.94m

16.8x

P/S Ratio

-84.3x

P/E Ratio

Is PHILM overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
PHILM income statement (TTM)
Revenue	€26.94m
Cost of Revenue	€13.19m
Gross Profit	€13.75m
Other Expenses	€19.13m
Earnings	-€5.38m

Last Reported Earnings

Dec 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)	-0.19
Gross Margin	51.05%
Net Profit Margin	-19.96%
Debt/Equity Ratio	4.0%

How did PHILM perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2023/07/18 17:00
End of Day Share Price	2023/04/20 00:00
Earnings	2022/12/31
Annual Earnings	2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Philogen S.p.A. is covered by 5 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Keyur Parekh	Goldman Sachs
Rajan Sharma	Goldman Sachs
Victor Floch	Stifel, Equities Research